Article
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2014
Jain Nitin, Curran Emily, Iyengar Neil M, Diaz-Flores Ernesto, Kunnavakkam Rangesh, Popplewell Leslie, Kirschbaum Mark H, Karrison Theodore, Erba Harry P, Green Margaret, Poire Xavier, Koval Greg, Shannon Kevin, Reddy Poluru L, Joseph Loren, Atallah Ehab L, Dy Philip, Thomas Sachdev P, Smith Scott E, Doyle L Austin, Stadler Walter M, Larson Richard A, Stock Wendy, Odenike Olatoyosi
Abstract excerpt
PURPOSE: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. EXPERIMENTAL DESIGN: Selumetinib is an oral small-molecule inhibitor of MAP-ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.